Hancock Jaffe Sells $41.4M In Stock To Fund Venous Therapies

The new public offering will fund the US pivotal trial of the company’s VenoValve device to treat chronic deep venous insufficiency in the legs.

• Source: shutterstock.com (Shutterstock)

Hancock Jaffe Laboratories will fund a pivotal trial of its VenoValve device to treat lower limb chronic deep venous insufficiency with $41.4m raised in a new public stock offering completed on 11 February.

The company sold nearly 6 million shares of common stock and warrants to purchase nearly 3 million common shares, exceeding its original expectations for the offering. On 9 February, the company announced it planned to raise about $36m by selling about 5

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Financing

More from Business